Health Care Related Organization
Roche Revisits Dyno for AAV Technology with $50M Upfront Payment
Roche, Dyno Therapeutics, AAV technology, gene therapy, neurological diseases, strategic partnership
Vabysmo’s Growth Pace Slows in Q3, Still on Track for Dominance in Eye Disease Market
Vabysmo, Roche, Regeneron, Eylea HD, eye disease market, vascular endothelial growth factor A (VEGF-A) therapy, age-related macular degeneration (AMD), diabetic macular edema (DME).
Pfizer Secures FDA Approval to Expand RSV Vaccine Abrysvo for High-Risk Adults Aged 18-59
Pfizer, RSV vaccine, Abrysvo, FDA approval, high-risk adults, immunocompromised adults
Novo Nordisk Seeks FDA Ban on Compounded Semaglutide Formulations Amid Safety Concerns
Novo Nordisk, FDA, semaglutide, compounding pharmacies, safety concerns, GLP-1 medications, weight loss drugs, diabetes treatments
Federal Court Dismisses Novartis’ Challenge to Inflation Reduction Act, Marking Sixth Win for Government
Inflation Reduction Act, IRA lawsuit, Novartis, Medicare Drug Price Negotiation Program, federal court, pharmaceutical industry, government victory
HLTH24: Atropos Health Introduces AI-Powered Chat Co-Pilot for Rapid Real-World Evidence Generation
Atropos Health, HLTH24, Chat-Based AI Co-Pilot, Real-World Evidence, Generative AI, Healthcare Evidence Generation, GENEVA OS, ChatRWD
Roche Abandons Tau Antibody Project, Returns Rights to UCB After $120M Investment
Roche, UCB, tau antibody, Alzheimer’s disease, bepranemab, $120M investment
Starboard Value Criticizes Pfizer Leadership Over Underperforming R&D and Overpriced Acquisitions
Pfizer Inc., Starboard Value, Activist Investor, Pharmaceutical Industry, R&D Underperformance, Overpaid M&A Deals, Corporate Accountability
Starboard Value Targets Kenvue for Revitalization Following $1B Stake in Pfizer
Starboard Value, Kenvue, Johnson & Johnson, Pfizer, activist investor, consumer health, pharmaceuticals
FDA Places Clinical Hold on Novavax’s COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates Due to Rare Adverse Event
Novavax, FDA, COVID-19, Influenza, Vaccine, Clinical Hold, Motor Neuropathy